-- Earnings Flash (MCRB) SERES THERAPEUTICS Posts Q1 Revenue $1.5M
7:02AM ET 5/04/2022 MT Newswires...
Quotes Snapshot > MCRB
Seres Therapeutics Inc MCRB:NASDAQ
Last Price$3.34NASDAQ Previous Close - Last Trade as of 4:00PM ET 5/18/22
Today's Change-0.28(7.73%)
Bid (Size)$3.30 (12)
Ask (Size)$3.34 (1)
Day Low / High$3.22 - 3.61
Volume947.5 K
Read more news Recent News
Seres Says Preclinical Data Show SER-155 Reduces Infection, Graft-Versus-Host-Disease
9:15AM ET 3/18/2022 MT NewswiresSeres Therapeutics (MCRB) said Friday that recent preclinical data show SER-155, an investigational microbiome therapeutic, reduces infection and...
--Oppenheimer Adjusts Seres Therapeutics Price Target to $13 From $16, Maintains Outperform Rating
10:46AM ET 3/02/2022 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Seres Therapeutics Q4 Net Loss Narrows as Revenue Increases
7:54AM ET 3/01/2022 MT NewswiresSeres Therapeutics (MCRB) reported a Q4 net loss Tuesday of $0.72 per diluted share, narrowing from a $1.12 loss a year earlier. Analysts polled by...
View all Commentary and Analysis
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q1 2022 Results - Earnings Call Transcript
1:12PM ET 5/04/2022 Seeking AlphaUpdate On Evogene's Subsidiaries: Biomica, Lavie Bio And AgPlenus
10:48AM ET 3/22/2022 Seeking AlphaSeres Therapeutics Is Playing A Long Game
7:00AM ET 3/06/2022 Seeking AlphaSeres Therapeutics (MCRB) Presents At Chardan's Microbiome and Metagenomics Summit - Slideshow
1:24PM ET 3/02/2022 Seeking AlphaCompany Profile
Business DescriptionSeres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA. View company web site for more details
| Address | 200 Sidney Street Cambridge, Massachusetts 02139 |
| Phone | +1.617.945.9626 |
| Number of Employees | 145 |
| Recent SEC Filing | 05/06/2022 EFFECT |
| President, Chief Executive Officer & Director | Eric D. Shaff |
| Senior Vice President-Operations | Marcus Chapman |
| EVP, Chief Financial & Accounting Officer | David A. Arkowitz |
| Chief Scientific Officer & Executive VP | Matthew R. Henn |
Company Highlights
| Price Open | $3.58 |
| Previous Close | $3.34 |
| 52 Week Range | $3.22 - 25.06 |
| Market Capitalization | $308.0 M |
| Shares Outstanding | 92.2 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 08/02/2022 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$0.97 |
| Beta vs. S&P 500 | N/A |
| Revenue | $28.3 M |
| Net Profit Margin | -61.65% |
| Return on Equity | -70.91% |
Analyst Ratings as of 03/02/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |